Cargando…
The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial
BACKGROUND: Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves’ disease. OBJECTIVE: This study aimed to investigate the effect of antithyroid drugs o...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721229/ https://www.ncbi.nlm.nih.gov/pubmed/34987480 http://dx.doi.org/10.3389/fendo.2021.796194 |
_version_ | 1784625295546908672 |
---|---|
author | Wisnu, Wismandari Alwi, Idrus Nafrialdi, Nafrialdi Harimurti, Kuntjoro Pemayun, Tjokorda Gede D. Jusman, Sri Widia A. Santoso, Dewi Irawati S. Harahap, Alida R. Suwarto, Suhendro Subekti, Imam |
author_facet | Wisnu, Wismandari Alwi, Idrus Nafrialdi, Nafrialdi Harimurti, Kuntjoro Pemayun, Tjokorda Gede D. Jusman, Sri Widia A. Santoso, Dewi Irawati S. Harahap, Alida R. Suwarto, Suhendro Subekti, Imam |
author_sort | Wisnu, Wismandari |
collection | PubMed |
description | BACKGROUND: Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves’ disease. OBJECTIVE: This study aimed to investigate the effect of antithyroid drugs on markers of vascular atherosclerosis in Graves’ hyperthyroidism. METHODS: This study was a single-blind, randomized clinical trial conducted on 36 patients with Graves’ disease in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from June 2019 until July 2020. Graves’ disease was diagnosed from clinical manifestation of hyperthyroidism with diffuse goiter and then confirmed by thyroid stimulation hormone (TSH), free T4 (fT4), and TSH-receptor antibody (TRAb) measurements. Participants were randomly assigned to either a PTU or a methimazole treatment group and followed up for 3 months. Markers of vascular atherosclerosis were represented by adhesion molecules [intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin], carotid artery stiffness [pulse wave velocity (PWV)], and thickness [carotid intima media thickness (cIMT)]. RESULTS: By the end of the study, 24 participants reached euthyroid condition (13 from the PTU group and 11 from the methimazole group). After 3 months of follow-up, in the PTU group, we noticed an improvement of ICAM-1 [pretreatment: 204.1 (61.3) vs. posttreatment: 141.6 (58.4) ng/ml; p = 0.001], VCAM-1 [837 (707–977) vs. 510 (402–630) ng/ml; p < 0.001] and E-selectin [32.1 (24.1–42.7) vs. 28.2 (21.6–36.8) ng/ml; p = 0.045] in the PTU group. In the methimazole group, only VCAM-1 improvement [725 (565–904) vs. 472 (367–590); p = 0.001] was observed. Meanwhile, we found no significant changes in PWV or cIMT in either group. CONCLUSION: Antithyroid treatment in Graves’ disease leads to improvement in adhesion molecules, with a lesser effect on methimazole, whereas there were no significant changes in PWV or cIMT. PTU may have a better mechanism compared with methimazole in terms of improving adhesion molecules. |
format | Online Article Text |
id | pubmed-8721229 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87212292022-01-04 The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial Wisnu, Wismandari Alwi, Idrus Nafrialdi, Nafrialdi Harimurti, Kuntjoro Pemayun, Tjokorda Gede D. Jusman, Sri Widia A. Santoso, Dewi Irawati S. Harahap, Alida R. Suwarto, Suhendro Subekti, Imam Front Endocrinol (Lausanne) Endocrinology BACKGROUND: Hyperthyroidism is related to vascular atherosclerosis. Propylthiouracil (PTU) and methimazole, other than their antithyroid effects, may have different mechanisms in preventing atherogenesis in Graves’ disease. OBJECTIVE: This study aimed to investigate the effect of antithyroid drugs on markers of vascular atherosclerosis in Graves’ hyperthyroidism. METHODS: This study was a single-blind, randomized clinical trial conducted on 36 patients with Graves’ disease in Cipto Mangunkusumo General Hospital, Jakarta, Indonesia, from June 2019 until July 2020. Graves’ disease was diagnosed from clinical manifestation of hyperthyroidism with diffuse goiter and then confirmed by thyroid stimulation hormone (TSH), free T4 (fT4), and TSH-receptor antibody (TRAb) measurements. Participants were randomly assigned to either a PTU or a methimazole treatment group and followed up for 3 months. Markers of vascular atherosclerosis were represented by adhesion molecules [intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin], carotid artery stiffness [pulse wave velocity (PWV)], and thickness [carotid intima media thickness (cIMT)]. RESULTS: By the end of the study, 24 participants reached euthyroid condition (13 from the PTU group and 11 from the methimazole group). After 3 months of follow-up, in the PTU group, we noticed an improvement of ICAM-1 [pretreatment: 204.1 (61.3) vs. posttreatment: 141.6 (58.4) ng/ml; p = 0.001], VCAM-1 [837 (707–977) vs. 510 (402–630) ng/ml; p < 0.001] and E-selectin [32.1 (24.1–42.7) vs. 28.2 (21.6–36.8) ng/ml; p = 0.045] in the PTU group. In the methimazole group, only VCAM-1 improvement [725 (565–904) vs. 472 (367–590); p = 0.001] was observed. Meanwhile, we found no significant changes in PWV or cIMT in either group. CONCLUSION: Antithyroid treatment in Graves’ disease leads to improvement in adhesion molecules, with a lesser effect on methimazole, whereas there were no significant changes in PWV or cIMT. PTU may have a better mechanism compared with methimazole in terms of improving adhesion molecules. Frontiers Media S.A. 2021-12-20 /pmc/articles/PMC8721229/ /pubmed/34987480 http://dx.doi.org/10.3389/fendo.2021.796194 Text en Copyright © 2021 Wisnu, Alwi, Nafrialdi, Harimurti, Pemayun, Jusman, Santoso, Harahap, Suwarto and Subekti https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Wisnu, Wismandari Alwi, Idrus Nafrialdi, Nafrialdi Harimurti, Kuntjoro Pemayun, Tjokorda Gede D. Jusman, Sri Widia A. Santoso, Dewi Irawati S. Harahap, Alida R. Suwarto, Suhendro Subekti, Imam The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial |
title | The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial |
title_full | The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial |
title_fullStr | The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial |
title_full_unstemmed | The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial |
title_short | The Differential Effects of Propylthiouracil and Methimazole as Graves’ Disease Treatment on Vascular Atherosclerosis Markers: A Randomized Clinical Trial |
title_sort | differential effects of propylthiouracil and methimazole as graves’ disease treatment on vascular atherosclerosis markers: a randomized clinical trial |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721229/ https://www.ncbi.nlm.nih.gov/pubmed/34987480 http://dx.doi.org/10.3389/fendo.2021.796194 |
work_keys_str_mv | AT wisnuwismandari thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT alwiidrus thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT nafrialdinafrialdi thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT harimurtikuntjoro thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT pemayuntjokordageded thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT jusmansriwidiaa thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT santosodewiirawatis thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT harahapalidar thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT suwartosuhendro thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT subektiimam thedifferentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT wisnuwismandari differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT alwiidrus differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT nafrialdinafrialdi differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT harimurtikuntjoro differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT pemayuntjokordageded differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT jusmansriwidiaa differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT santosodewiirawatis differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT harahapalidar differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT suwartosuhendro differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial AT subektiimam differentialeffectsofpropylthiouracilandmethimazoleasgravesdiseasetreatmentonvascularatherosclerosismarkersarandomizedclinicaltrial |